Some patients reluctantly shifted to save money while others have appealed for coverage of Zepbound after having experienced ...

The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should see earnings gains through the end of the decade.

More than 80 U.S. lawmakers asked the FDA to stop counterfeit GLP-1 drugs linked to Chinese suppliers from entering the ...

China's Sciwind Biosciences is in talks with a U.S. company interested in licensing its experimental weight-loss drug for ...

Several anti-obesity drugs, including Ozempic, Wegovy and Mounjaro, have created buzz in the Indian markets. But are they really approved for use in India? What are their side-effects? And how much do ...

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

Wegovy is a semiglutide medication and helps manage weight loss and cardiovascular health. Though the two drugs are both approved for weight loss, a study published in May funded by Eli Lilly found ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. The medications still amount to around $500 per month for those without ...

Novo Nordisk A/S’ (NYSE:NVO) executives allegedly ignored internal warnings that the company was unprepared to launch its ...

An investigation by Democratic senators has raised concerns about conflicts of interest in telehealth companies' ties to ...

Pharmaceutical giant Eli Lilly that new preliminary research indicates its medication Zepbound helps patients lose more weight in a shorter time frame compared to Novo Nordisk's Wegovy. According ...

Wegovy launch in India challenges Eli Lilly's Mounjaro Analysts say Wegovy priced competitively to Mounjaro Novo faces competition from generic drugmakers Wegovy 0.25 mg, 0.5 mg and 1 mg available ...